Abstract
Highlights| September 01 2022 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2022 American Association for Cancer Research2022American Association for Cancer Research Clin Cancer Res (2022) 28 (17): 3631. https://doi.org/10.1158/1078-0432.CCR-28-17-HI Related Content A commentary has been published: A Cathepsin-Targeted Quenched Activity–Based Probe Facilitates Enhanced Detection of Human Tumors during Resection A commentary has been published: Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403) A commentary has been published: Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis View more A commentary has been published: First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 1 2022 Citation Selected Articles from This Issue. Clin Cancer Res 1 September 2022; 28 (17): 3631. https://doi.org/10.1158/1078-0432.CCR-28-17-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Diffuse large B-cell lymphoma (DLBCL) is recognized as a heterogeneous disease that can be cured in up to 60–70% of the cases with upfront therapy. However, relapsed/refractory DLBCL (R/R DLBCL) still represents a great clinical challenge. Palazón-Carrión and colleagues conducted an open label multicenter phase 2 trial (R2-GDP-GOTEL) testing the synergism of combination lenalidomide (LEN) and rituximab (R2) plus gemcitabine, cisplatin, dexamethasone (R2-GDP schedule) in R/R DLBCL patients, not suitable for autologous stem cell transplantation. Results suggest that LEN in combination with R-GDP (R2-GDP schedule) is an immunomodulatory treatment option with manageable toxicity and promising clinical activity, with high proportion of complete responses and favorable survival outcomes in patients with R/R DLBCL. Additionally, evolution of MDSC and Treg in peripheral blood seem an alternative for monitoring immune profiling that is related to clinical outcomes of overall survival and complete responses. In the first-in-human phase I/II ICONIC trial, Yap and colleagues... You do not currently have access to this content.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
